Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611180 · ClinicalTrials.gov registry record
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
A clinical trial of Chronic Graft Versus Host Disease and Acute-graft-versus-host Disease, sponsored by Washington University School of Medicine.
- Active
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT02611180: Active study of Chronic Graft Versus Host Disease and Acute-graft-versus-host Disease, sponsored by Washington University School of Medicine.
NCT02611180 is a study of Chronic Graft Versus Host Disease and Acute-graft-versus-host Disease that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 22 participants, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02611180, a study of Chronic Graft Versus Host Disease and Acute-graft-versus-host Disease, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Primary Outcome
* Both GVHD affected and unaffected skin sections will be analyzed by immunostaining and the types of cells and strains of skin microbiota present will be analyzed * The different isolated DCs will be activated by different stimuli and will be characterized by gene (DNA, RNA sequencing or arrays) and multicolor flow cytometry analysis.
Conditions Studied
Interventions
- PROCEDURE Peripheral blood draw
- PROCEDURE Skin punch biopsy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2027-04-30 |
What the registry record for NCT02611180 still lists
NCT02611180 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Peripheral blood draw is the first listed.
NCT02611180 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02611180 about?
NCT02611180 is a clinical study titled "Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease". Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC s...
What is the current status of trial NCT02611180?
This trial is currently active not recruiting. The enrollment target is 22 participants. The study started on 2015-04-30. Estimated completion is 2027-04-30.
What conditions does trial NCT02611180 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease, Acute-graft-versus-host Disease, Chronic GVHD, Acute GVHD.
What interventions are being tested in trial NCT02611180?
The interventions under investigation include: Peripheral blood draw (PROCEDURE), Skin punch biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02611180?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02611180 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02611180's enrollment target sits among peer trials
22 24th of 30 higher than 7 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI